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E-mail address: eitsuka@nupals.ac.jp (T. Eitsuka).Several lines of experimental data have highlighted a key role of Amadori-glycated phosphatidyleth-
anolamine (Amadori-PE) in the development of diabetic complications. Recent epidemiological
studies suggest that diabetes mellitus could be a risk factor for some cancers. A characteristic of can-
cer cells is their immortal phenotype, and the enzyme telomerase contributes to the inﬁnite repli-
cative potential of cancer cells. The purpose of this study was to obtain new information about the
effect of Amadori-PE on the regulation of telomerase in PANC-1 human pancreatic carcinoma cells.
Amadori-PE enhanced cellular telomerase in a time- and dose-dependent manner by up-regulating
hTERT expression through induction of c-myc. These results provide experimental evidence for a
novel role of Amadori-PE in linking diabetes and cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Non-enzymatic protein glycation and its involvement in
diabetic complications have been thoroughly investigated [1]. In
addition to the protein glycation, we and some researchers have
found that glycation reaction also occurs in vivo between lipids
and glucose [2–4]. It suggests that membrane phospholipids such
as phosphatidylethanolamine (PE) are abnormally glycated under
hyperglycemic conditions and that lipid glycation may contribute
to the pathogenesis of diabetic complications (e.g., retinopathy,
nephropathy, neuropathy, and atherosclerotic macrovascular dis-
ease). We previously investigated the pathophysiological impact
of lipid glycation in vitro and found that Amadori-PE (an early
glycation product of PE; Fig. 1) caused lipid peroxidation [5] and
angiogenesis [6]. We also developed a sensitive assay for Amado-
ri-PE and demonstrated its accumulation in blood plasma of
diabetic patients [7]. Knowledge gained from these studies [2–7]
provides insight into involvement of Amadori-PE in the pathogen-
esis of diabetic complications.
Numerous epidemiologic studies suggest that type 2 diabetes
signiﬁcantly increases overall cancer risk and mortality [8,9]. One
of the malignancies adversely affected by type 2 diabetes is pancre-chemical Societies. Published by Eatic cancer. Recent meta-analysis estimated that individuals with
diabetes have a two-fold greater relative incidence of pancreatic
cancer compared with individuals without diabetes [10], raising
the possibility that diabetes could be a risk factor for pancreatic
cancer.
Telomerase is a nuclear ribonucleoprotein enzyme complex
with reverse transcriptase activity that is responsible for the exten-
sion of telomeric DNA and that could be linked to cellular senes-
cence and immortalization [11]. In human cells, the enzyme
comprises three main components, hTR (human telomerase RNA
component) [12], TP1 (telomerase-associated protein 1) [13], and
hTERT (human telomerase reverse transcriptase) [14,15], the last
of which plays a key role in telomerase activation. Telomerase is
present in germ line cells, cancer-derived cell lines and spontane-
ously immortalized cells in culture, whereas the enzyme is usually
not expressed in normal somatic cells that results in the progres-
sive loss of telomeres with each cell division [16]. These ﬁndings
clearly indicate that telomerase is essential for cell immortaliza-
tion and tumorigenesis.
Although there are many epidemiologic researches suggesting
the involvement of diabetes in tumor development, little is known
regarding the molecular mechanism underlying this phenomenon
to date. Hence, in this study, we hypothesized that Amadori-PE
may participate not only in the pathogenesis of diabetic complica-
tions but also in tumor progression. In the present study, thislsevier B.V. All rights reserved.
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Fig. 1. Scheme for the glycation of PE. Glucose reacts with the amino group of PE to form a Schiff base, which then undergoes rearrangement to yield deoxy-D-fructosyl PE
(Amadori-PE).
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emphasis on the effect of Amadori-PE on telomerase activity, using
PANC-1 human pancreatic carcinoma cells.
2. Materials and methods
2.1. Materials
1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoeth-
anolamine (16:0–18:1 PE) was purchased from Avanti Polar Lipids
(Alabaster, AL). Amadori-PE was prepared from a glycation system
of 16:0-18:1 PE/glucose by a high-performance liquid chromatog-
raphy technique as described previously [5]. RPMI 1640 medium
(containing 0.3 mg/ml L-glutamine and 2.0 mg/ml sodium bicar-
bonate) was purchased from Sigma (St. Louis, MO). Fetal bovine
serum (FBS) was from Funakoshi (Tokyo, Japan). Penicillin and
streptomycin were products of Gibco BRL (Rockville, MD). 3-(4,
5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was produced by Dotite (Kumamoto, Japan). 10058-F4 was ob-
tained from Merck Millipore (Darmstadt, Germany). All other
reagents were of analytical grade.
2.2. Cell culture
PANC-1 (human pancreatic carcinoma) cells were provided by
the RIKEN BRC (Tsukuba, Japan). Cells were precultured in growth
medium (RPMI-1640 medium supplemented with 10% FBS, 100
units/ml penicillin and 100 lg/ml streptomycin) at 37 C in a
humidiﬁed atmosphere of 95% air and 5% CO2.
2.3. Preparation of Amadori-PE for cell cultures
A portion of 0.5 mM Amadori-PE in methanol was placed in a
sterile tube and the solvent was removed by a N2 gas ﬂux. The
dried Amadori-PE was dispersed in the medium using sonication,
followed by dilution with medium to achieve the desired ﬁnal con-
centration. Sample-free medium was employed as controls for the
present study.
2.4. MTT dye reduction assay
PANC-1 cells were seeded onto a 96-well plate at a density of
1.0  104 cells/well in 100 ll of growth medium. After incubation
for 24 h, the medium was removed, and the cells were cultured
in 100 ll of test medium. Then, PANC-1 proliferation was assessed
by the MTT method [17].2.5. Detection of telomerase activity
Telomerase activity was determined by the stretch PCR assay
[18] using a TeloChaser Kit (Toyobo, Osaka, Japan) which includes
a 65-base pair internal control to allow quantiﬁcation of activity.
Brieﬂy, Amadori-PE-treated and non-treated cells, grown in 6-cm
dishes, were rinsed twice with phosphate buffered saline and sus-
pended in lysis buffer (Toyobo). Then, the cell lysate (20 ll; equiv-
alent to 1.5  104 cells) was subjected to stretch PCR assay. The
PCR product was electrophoresed on a 10% non-denaturing poly-
acrylamide gel and visualized with ethidium bromide (Invitrogen,
Carlsbad, CA). Relative telomerase activity was determined by
measuring the band intensities of all six-base ladders, and compar-
ing them with those of internal standard. Band intensity was mea-
sured using Scion Image Beta 4.02 picture analyzing software for
Windows (Scion Corporation, Frederick, MD).
2.6. Isolation of total RNA and analysis of mRNA expression
For real-time quantitative reverse transcriptase-PCR (RT-PCR),
total RNA was isolated from the cells with RNeasy total RNA
extraction kit (Qiagen, Hilden, Germany), and cDNA was synthe-
sized using PrimeScript RT reagent kit (Takara, Ohtsu, Japan). The
cDNA was subjected to PCR ampliﬁcation using SYBR Premix Ex
Taq II (Takara) and gene speciﬁc primers for hTR [19], hTERT,
c-myc and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Takara). Quantitative PCR was performed with the Thermal Cycler
Dice Real Time System (Takara), which allows real-time quantita-
tive detection of the PCR product by measuring the increase in
ﬂuorescence caused by the binding of SYBR Green to double-strand
DNA. The thermal cycling conditions comprised an initial denatur-
ation step at 95 C for 10 s and 40 cycles of 95 C for 5 s and 60 C
for 30 s.
2.7. Western blot analysis
SDS–polyacrylamide gel electrophoresis was carried out by the
procedure of Laemmli [20] using 10% acrylamide gels. The protein
bands were transferred to polyvinylidine ﬂuoride membrane (GE
Healthcare, Buckinghamshire, UK). After being blocked, the mem-
brane was probed with primary antibodies, followed by an alkaline
phosphatase-conjugated secondary antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA). The detection of the antibody was per-
formed by the addition of 4-nitro blue tetrazolium chloride and
5-bromo-4-chloro-3-indolyl-phospate substrate in staining buffer
(100 mM Tris, 100 mM NaCl, and 50 mM MgCl2 (pH 9.5)). The
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anti-c-Myc (Santa Cruz Biotechnology) and anti-GAPDH (Santa
Cruz Biotechnology).
2.8. Statistical analysis
Data represent the means ± S.D. of at least three independent
experiments. Statistical differences between control and the corre-
sponding Amadori-PE treatments were determined by one-way
analysis of variance (ANOVA) followed by Dunnett’s test. P-values
<0.05 were considered signiﬁcant.
3. Results
Before the evaluation of telomerase activity, the effect of Ama-
dori-PE on PANC-1 proliferation was investigated. As shown in
Fig. 2, Amadori-PE dose-dependently induced the growth rate of
PANC-1 cells, whereas non-glycated PE showed no change in cell
growth compared with the control. The enhancing effect of Ama-
dori-PE on cell proliferation peaked at a concentration of 5 lM.
From this result, Amadori-PE at the concentrations of 5 lM or less
was chosen for the telomerase experiments.
Telomerase activity was examined using a semi-quantitative
telomerase assay (stretch PCR) [18]. In this assay, DNA ampliﬁed
from telomerase products by the stretch PCR reaction was sepa-
rated by electrophoresis and detected on the gel as a ladder con-
sisting of bands spaced six base pairs apart (refer to the ladder
presented for control in Fig. 3A). After culturing PANC-1 cells
with 5 lM Amadori-PE for 48 h, an increase in intensity of the
six-base ladders was documented (Fig. 3A), indicating that Ama-
dori-PE can modulate telomerase activity. Fig. 3B shows that
treatment of PANC-1 cells with 0.25–5 lM Amadori-PE for 48 h
resulted in a dose-dependent elevation in telomerase activity.
To examine the time-dependent telomerase modulation, PANC-
1 cells were cultured with 5 lM Amadori-PE for 6–72 h. Telome-
rase activity was time-dependently elicited, and this effect
apparent at 6 h after cultivation (Fig. 3C). On the other hand, in-
tact PE had virtually no effect on telomerase activity (Fig. 3A and
B).
hTERT is the catalytic subunit of telomerase, and it plays an
important role in telomerase activation [21]. Therefore, to evaluate
the molecular mechanism for telomerase regulation by Amadori-
PE, we investigated the effect of Amadori-PE on hTERT expression
in PANC-1 cells using a real-time RT-PCR. As shown in Fig. 4A,
Amadori-PE effectively evoked the expression of hTERT mRNA in
a dose-dependent manner, indicating that telomerase activity is120
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Fig. 2. Effect of Amadori-PE on the PANC-1 proliferation. PANC-1 cells grown in 96-
well plates were treated with 0.05–5 lM Amadori-PE or 5 lM PE or without sample
(control) for 48 h. The viable cells were then evaluated by MTT assay and are
expressed as a percentage of the control. Values are means ± S.D. from six
independent experiments.
Fig. 3. Cellular telomerase activity is increased by treatment with Amadori-PE. (A)
PANC-1 cells were cultured with or without test samples (0.25–5 lM Amadori-PE
or 5 lM PE) for 48 h. Subsequently, telomerase activity in the cell extracts was
measured by the stretch PCR assay. The PCR product was separated by 10% non-
denaturing polyacrylamide gel electrophoresis and visualized with ethidium
bromide. (B) The dose-dependent induction of telomerase activity was evaluated
by treating PANC-1 cells with 0.25–5 lM Amadori-PE or without sample (control)
for 48 h. (C) The time-dependent induction of telomerase activity was investigated
by treating PANC-1 cells in the presence or absence of 5 lM Amadori-PE for 6–72 h.
Telomerase activity is expressed as a percentage of the control. Values are
means ± S.D. from three independent experiments; ⁄P < 0.05 compared with
control.controlled at the transcriptional level. In addition, to ascertain
the effect of Amadori-PE on hTERT mRNA induction, we measured
the expression of hTERT protein in response to Amadori-PE treat-
ment by Western blot analysis. Amadori-PE caused a remarkable
increase in hTERT protein level (Fig. 4B). On the other hand, Ama-
dori-PE had no effect on the mRNA levels of hTR, template RNA
component of telomerase (data not shown).
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Fig. 4. Effects of Amadori-PE on hTERT expression. PANC-1 cells were treated in the
presence or absence of Amadori-PE for 48 h. mRNA (A) and protein (B) levels of
hTERT in response to Amadori-PE were then measured by real-time RT-PCR and
Western blotting, respectively, and are expressed as percentages of the control.
Values are means ± S.D. from three independent experiments; ⁄P < 0.05 compared
with control.
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Fig. 5. Effects of Amadori-PE on c-myc expression. mRNA (A) and protein (B) levels
of c-myc in response to Amadori-PE at 48 h were measured by real-time RT-PCR
and Western blotting, respectively, and are expressed as percentages of the control.
(C) PANC-1 cells were treated with 5 lM Amadori-PE and/or 64 lM 10058-F4 or
without sample for 48 h. Cellular telomerase activity was then evaluated by the
stretch PCR assay. Values are means ± S.D. from three independent experiments;
⁄P < 0.05 compared with control.
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expression [22], we then examined and found that treatment of
PANC-1 cells with Amadori-PE resulted in a signiﬁcant elevation
in c-myc mRNA expression (Fig. 5A). As seen in Fig. 5B, c-Myc
protein level was dose-dependently increased in response to
Amadori-PE treatment. In an attempt to ascertain if c-Myc is
required for telomerase activation by Amadori-PE, the effect of
10058-F4, a c-Myc inhibitor, on telomerase was examined in
Amadori-PE-treated PANC-1 cells. 10058-F4 can speciﬁcally block
c-Myc/Max dimerization, thereby preventing c-Myc DNA binding
and target gene expression [23]. As shown in Fig. 5C, after treat-
ment of the cells with 64 lM 10058-F4 for 48 h, telomerase activ-
ity was markedly reduced to about 20%. Telomerase activation in
response to Amadori-PE was completely inhibited when 10058-
F4 was added simultaneously with 5 lM Amadori-PE (Fig. 5C),
indicating that telomerase induction by Amadori-PE can be
attributed to up-regulation of c-Myc. Taken together, these
observations indicate that Amadori-PE elicits cellular telomerase
activity by up-regulating hTERT mRNA expression through
induction of c-myc expression.
4. Discussion
In this study, we demonstrated for the ﬁrst time that Amadori-
PE signiﬁcantly elicited telomerase activity in PANC-1 cells (Fig. 3).
To elucidate whether the observation is generally applicable, we
tested the effect of Amadori-PE on telomerase activity in MIA
PaCa-2 human pancreatic carcinoma, DLD-1 human colorectal
adenocarcinoma, HepG2 human hepatoma, HeLa human cervical
carcinoma and MCF-7 human breast adenocarcinoma. Inconsequence, Amadori-PE signiﬁcantly induced telomerase activity
in MIA PaCa-2, DLD-1 and HepG2 cell lines, but did not in HeLa and
MCF-7 cells (data not shown), suggesting that telomerase regula-
tion by Amadori-PE may depend on cell types. The concentration
range of 1–5 lM Amadori-PE that we used in our in vitro experi-
ments was comparable to the concentration of this lipid in the
plasma of patients with diabetes [3]. This indicates that our study
was performed under physiological concentrations of Amadori-PE.
In contrast, non-glycated PE had no effect on telomerase activity
(Fig. 3), suggesting that the telomerase activation was speciﬁc to
the Amadori-PE, but not to intact PE.
Since cancer cells but not most somatic cells possess telomerase
activity, the maintenance of telomeres by telomerase has been
implicated in tumorigenesis [16]. It is commonly thought that can-
cer cells enter crisis with short telomeres but then escape via the
up-regulation of telomerase and so exhibit an inﬁnite replicative
2546 T. Eitsuka et al. / FEBS Letters 586 (2012) 2542–2547capacity. Therefore, telomerase is a novel and potentially highly
selective target for cancer therapy. In such a context, there is con-
siderable work being undertaken to screen potential telomerase
inhibitors. In our recent studies, some lipids (i.e., sulfoquinvosyl-
diacylglycerol [24], polyunsaturated fatty acids [25] and tocotri-
enol [26]) appeared to act as powerful telomerase inhibitors.
Telomerase can augment cancer cell proliferation by increas-
ing the transcription of growth-controlling genes and promote
survival by abating apoptosis and facilitating DNA repair [27].
Further elevation of telomerase activity in tumor cells is associ-
ated with a more aggressive tumor phenotype [28]. In fact, telo-
merase inducers like genistein have been shown to remarkably
enhance tumor growth in vivo [29]. In light of our ﬁndings,
the relationship between Amadori-PE and telomerase activation
may, therefore, have relevance to the progression of human can-
cer, and Amadori-PE may be one of the important inducers of
cancer in vivo. We are now trying to investigate this possibility
using in vivo tumor models.
According to previous studies [21], there is a strong correlation
between the expression of hTERT mRNA and telomerase activity in
extracts from culture cells and tissues, whereas hTR is expressed
constitutively in both cancer and normal cells, irrespective of the
status of the telomerase expression. This ﬁnding strongly suggests
that hTERT is a rate-limiting determinant of telomerase activity. As
shown in Fig. 4A, we succeeded in demonstrating that culturing
PANC-1 cells with Amadori-PE induced a signiﬁcant increase in
hTERT mRNA expression, thereby eliciting telomerase activity.
The result indicates that Amadori-PE can regulate telomerase at
transcriptional level.
c-Myc recognizes and binds to the sequence CACGTG, termed an
E-box, on target gene promoters [30]. Since the hTERT promoter
contains two E-boxes in its core region, the expression of c-myc
has a parallel relation with the expression of hTERT [22]. Our re-
sults, therefore, indicate that Amadori-PE can up-regulate hTERT
expression in PANC-1 cells via elevation of c-myc expression
(Fig. 5). It is well-known that oncogene c-myc is involved in the
control of cell growth [31]. Thus, it is conceivable that increased
c-myc expression elicits not only up-regulation of hTERT but also
induction of cell growth. This was supported by proportional cor-
relations among hTERT (Fig. 4), c-myc (Fig. 5) and growth rate in
PANC-1cells (Fig. 2).
We have previously shown that Amadori-PE could be an origin
compound for generating reactive oxygen species (ROS) [5]. ROS
activate signal transduction cascade, such as protein kinase C
(PKC) [32], leading to modulation of many genes and proteins in-
volved in diabetes. Both direct activators of PKC and hormones
which induce PKC via receptor-mediated phosphoinositide turn-
over evoke a rapid increase in c-myc mRNA expression [33], sug-
gesting that c-myc expression is controlled through a PKC
signaling pathway. It is therefore plausible that up-regulation of
c-myc (Fig. 5) might be due to the induction of PKC through ROS
generation by Amadori-PE. Further elucidation of detailed molecu-
lar mechanisms and precise molecular targeting of telomerase reg-
ulation by Amadori-PE are subjects of ongoing investigations.
To date, although a number of epidemiologic studies have sug-
gested a relationship between diabetes and cancer, there is no
information on the potential interactions between glycation and
cancer, especially for telomerase activity in cell-culture study. In
conclusion, we demonstrated for the ﬁrst time that Amadori-PE,
a lipid glycation product, elicited cellular telomerase activity in a
time- and dose-dependent manner. Amadori-PE modulated telo-
merase by up-regulating hTERT mRNA expression through induc-
tion of c-myc expression. These results indicate that Amadori-PE
may be an important compound that promotes tumor progression
as a result of telomerase activation and provide experimental evi-
dence for a novel role of Amadori-PE in linking diabetes and cancer.References
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